FAQs
What is the long term debt of Moderna? ›
Compare MRNA With Other Stocks
| Moderna Debt/Equity Ratio Historical Data | ||
|---|---|---|
| Date | Long Term Debt | Shareholder's Equity |
| 2022-03-31 | $10.53B | $17.08B |
| 2021-12-31 | $10.52B | $14.15B |
| 2021-09-30 | $10.80B | $10.12B |
CAPM WACC Model
| Metrics | Range | Conclusion |
|---|---|---|
| Selected Beta | 0.89 - 1.04 | 0.96 |
| Cost Equity | 8.3% - 9.5% | 8.9% |
| Tax Rate | 14.0% - 14.0% | 14.0% |
| Cost Debt Aftax | 4.7% - 5.2% | 4.9% |
Moderna cash on hand for 2023 was $8.604B, a 13.11% decline from 2022. Moderna cash on hand for 2022 was $9.902B, a 7.69% decline from 2021. Moderna cash on hand for 2021 was $10.727B, a 132.79% increase from 2020.
Does Moderna have debt? ›Total debt on the balance sheet as of December 2023 : $1.24 B. According to Moderna 's latest financial reports the company's total debt is $1.24 B. A company's total debt is the sum of all current and non-current debts.
How much money has Moderna made from COVID vaccine? ›JPM23: Moderna reaped $18.4B in COVID vaccine sales last year, projects at least $5B in 2023. Throughout 2022, headlines regularly documented the decline in COVID-19 vaccine demand, prompting market watchers to wonder how the leading manufacturers would fare on the sales front.
What does Moderna make money on? ›Moderna Revenue Breakdown: Product sales, 96%; Grant revenue, 4%; Collaboration revenue, a tiny fraction.
How much does it cost to produce Moderna vaccine? ›“Experts have estimated that a dose of the Moderna vaccine costs just $2.85 to produce. Increasing the price to $130 would be a mark-up of more than 4,000% above production cost.
What does the debt to equity ratio measure? ›The debt-to-equity ratio shows how much of a company is owned by creditors (people it has borrowed money from) compared with how much shareholder equity is held by the company. It is one of three calculations used to measure debt capacity—along with the debt servicing ratio and the debt-to-total assets ratio.
What is the profit and loss of Moderna? ›Net Income (Loss): Net loss was $(1.2) billion for the first quarter of 2024, compared to net income of $79 million for the first quarter of 2023. Earnings (Loss) Per Share: Diluted loss per share was $(3.07) for the first quarter of 2024, compared to diluted earnings per share of $0.19 for the first quarter of 2023.
What is the analyst rating of Moderna? ›What do analysts say about Moderna? Moderna's analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.
Is Moderna a good company to work for? ›
Moderna Reviews FAQs
Is Moderna a good company to work for? Moderna has an overall rating of 3.5 out of 5, based on over 707 reviews left anonymously by employees. 52% of employees would recommend working at Moderna to a friend and 51% have a positive outlook for the business.
After six months, Pfizer vaccine recipients had antibody levels lower than both the Moderna recipients and patients who had been hospitalized with severe COVID-19 six months prior. (Patients who suffer severe COVID are thought to generate more antibodies than people who recover from mild cases.)
Has Moderna ever had a successful vaccine? ›Continuing the spate of stunning news about COVID-19 vaccines, the biotech company Moderna announced the final results of the 30,000-person efficacy trial for its candidate in a press release today: Only 11 people who received two doses of the vaccine developed COVID-19 symptoms after being infected with the pandemic ...